Nogest (Nomegestrol Acetate)

Nomegestrol acetate, the active ingredient in Nogest, is a synthetic progestogen presented as an oral tablet for oral use. It is employed to prevent pregnancy and to provide progestogenic support in menopausal hormone therapy, acting on women of reproductive age and those requiring hormonal balance during menopause and is approved for use in the European Union.

GNH USA supplies Nogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for global health partners.

Nomegestrol acetate in Nogest is used in hormonal pathways to prevent pregnancy and to manage menopausal symptoms. - Oral contraception: prevents ovulation and pregnancy in women of reproductive age by providing progestogenic activity. - Menopausal hormone therapy: alleviates vasomotor symptoms and supports endometrial stability during estrogen‑containing regimens. - Cycle control: regulates menstrual bleeding patterns and reduces irregular spotting in women with hormonal imbalances.

Nomegestrol acetate may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: discomfort or swelling of breast tissue. - Weight gain: modest increase in body weight. - Irregular bleeding: spotting or changes in menstrual flow.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Liver dysfunction: elevated enzymes or hepatitis. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before prescribing Nogest, clinicians should evaluate several safety considerations to minimize risk. - Pregnancy: contraindicated in known or suspected pregnancy. - Breastfeeding: avoid unless benefits outweigh potential risks to the infant. - Smoking: caution in women over 35 who smoke due to increased thrombotic risk. - History of thromboembolism: not recommended for patients with prior clotting events. - Drug interactions: review concomitant medications that may affect efficacy or safety. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nomegestrol acetate can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Combined hormonal contraceptives containing estrogen: may increase risk of thromboembolism. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise plasma levels of nomegestrol acetate. - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Rifampicin and other potent inducers: may diminish hormonal activity. - St. John’s wort: may lower drug concentrations. - Certain antibiotics (e.g., clarithromycin): may modestly increase exposure.